Gansu sends out a signal: "4 + 7" prices may really be linked!

[China Pharmaceutical network industry trends] on December 19, Gansu Province Drug and medical consumables centralized purchase network issued the notice on the online transaction of youmeituomidine hydrochloride injection of Yangtze River Pharmaceutical Group Co., Ltd (hereinafter referred to as the notice) in the bid winning result of "4 + 7 urban drug centralized purchase" According to the notice, Gansu actively responded to the call of the state, communicated fully with relevant enterprises and encouraged enterprises to implement new bidding results in Gansu Province after the bidding result of "4 + 7 urban drug centralized procurement" pilot project of national drug centralized procurement was generated At present, Yangzijiang pharmaceutical industry actively applies for the bid price of dexmedetomidine hydrochloride injection (1ml: 0.1mg \ 2ml: 0.2mg) produced by it in Gansu Province Now, the drug is put on the Internet for transaction and unified price procurement in Gansu Province The result of putting on the Internet is implemented in Gansu Province since December 24, 2018 The notice stressed that all medical institutions should give priority to purchasing and using the drugs that have passed the consistency evaluation of generic drugs, open up a green channel for purchasing and using the winning drugs of "4 + 7 city drug centralized procurement", so that the reform dividend can benefit more people, and the people can use the drugs with better quality and lower price And encourage more enterprises to take the initiative to apply for reducing drug prices to benefit the people The industry believes that Gansu Province's notice sent a signal to the industry: "4 + 7" prices may really be linked! Before that, Anhui also heard the news of price linkage According to the industry, Anhui will organize experts to negotiate for 4 + 7 winning varieties The specific method is: randomly select experts from different hospitals to participate in the negotiation Each group of N personnel comes from different N hospitals and a team leader The company will send no more than three people to participate in the negotiation of independent products At the same time, it is required that the hospital must use negotiated products and ensure that 80% of the purchased products are purchased with volume If there is any problem in the implementation process of the hospital, the pharmaceutical enterprise can directly complain to the relevant parties Some experts in the industry pointed out that "under the premise that there are sufficient guarantees and equal rights and obligations in a series of supporting measures such as capacity commitment, distribution response, purchase and use, payment for goods, and medical insurance payment, non central selection regions are encouraged to link the mode and price when collecting 4 + 7 middle selection prices." Therefore, most of the industry believe that "4 + 7" winning drug price linkage is sooner or later Gansu Province, which started this time, is releasing more signals for the industry Price linkage may be a matter of time On December 20, the pilot working conference on centralized drug procurement organized by the state was held in Shanghai According to the participants, it was mentioned at the meeting that the implementation time of 4 + 7 volume procurement will be determined at the end of February next year and the beginning of March next year All regions will be implemented before March 15, 2019, and Shanghai will implement first In addition, in the first half of 2019, the state will issue specific implementation rules, while the local government will issue local implementation rules in mid January next year It is reported that this meeting is mainly for the bid winning pharmaceutical companies to ensure quality and supply requirements As we all know, the price of drugs dropped by an average of 52% when the bid winning result was announced for volume procurement Therefore, in this context of obvious price reduction, whether the pharmaceutical companies can guarantee the quality and whether the power production is the concern of the industry Now it is about to enter 2019, and the landing time of "4 + 7" volume procurement is also in the state Generally speaking, once it is landed, it means that the era of high gross profit and high profit of generic drugs will be over For companies with product lines, R & D and sales capabilities, it is a good thing in the long run.